Medexus Pharmaceuticals (CVE:MDP) Shares Down 4.9%

Medexus Pharmaceuticals Inc. (CVE:MDP)’s share price traded down 4.9% during trading on Monday . The stock traded as low as C$7.70 and last traded at C$7.75. 40,981 shares traded hands during mid-day trading, a decline of 40% from the average session volume of 68,619 shares. The stock had previously closed at C$8.15.

Analysts Set New Price Targets

Separately, Stifel Nicolaus cut their price objective on Medexus Pharmaceuticals from C$2.85 to C$2.35 in a research report on Thursday, February 22nd.

Medexus Pharmaceuticals Stock Down 4.9 %

The company has a debt-to-equity ratio of 1,174.36, a quick ratio of 0.74 and a current ratio of 1.19. The stock has a market capitalization of C$148.54 million and a PE ratio of -4.28. The business has a 50 day moving average of C$7.75 and a two-hundred day moving average of C$7.75.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older.